Aurinia Pharmaceuticals (AUPH) Return on Capital Employed (2021 - 2026)

Aurinia Pharmaceuticals has reported Return on Capital Employed for 6 years, with the latest figure at 19.12% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 1249.0% year-over-year to 19.12%; the trailing twelve-month figure through Mar 2026 stood at 19.12% (up 1249.0% YoY), and the FY2025 full-year result was 18.82%, up 1986.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 19.12%, down from 19.22% in the prior quarter.
• The five-year high for Return on Capital Employed was 19.22% in Q4 2025, with the low at 34.21% in Q1 2022.
• Historically, Return on Capital Employed has averaged 9.83% across 5 years, with a median of 16.34% in 2024.
• Annual changes were most pronounced in 2022 — Return on Capital Employed sank 373 bps — and 2025, when it soared 2592 bps.
• Aurinia Pharmaceuticals' Return on Capital Employed stood at 25.72% in 2022, then increased by 25 bps to 19.33% in 2023, then jumped by 95 bps to 1.04% in 2024, then soared by 1955 bps to 19.22% in 2025, then fell by 1 bps to 19.12% in 2026.
• The last three Return on Capital Employed figures came in at 19.12% (Q1 2026), 19.22% (Q4 2025), and 15.95% (Q3 2025), per Business Quant data.